Rifaximin to Modify the Disease Course in Sickle Cell Disease

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

PHASE2

Total Enrollment

20 participants

Study Classification

INTERVENTIONAL

Study Start Date

2018-08-22

Study Completion Date

2020-07-22

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

In this single-arm, one-stage Phase II study, the investigators hypothesize that gut decontamination with rifaximin will reduce the frequency of hospital admission due to painful crisis in patients with SCD. The study will accrue 20 SCD patients who had at least two hospital admissions in the previous 12 months. These patients will receive rifaximin 550 mg twice a day for a total of 12 months. This following clinical parameters will be measured: 1. Changes in the annual rate of hospital admissions due to painful crisis; 2. Changes in the annual rate of days hospitalized; 3. Annual rates of uncomplicated crises; 4. Annual rate of acute chest syndrome; 5. Changes in the quality of life; and 6). Toxicities. The following laboratory parameters will be measured: 1. Changes in the number of circulating activated neutrophils; 2. Changes in the intestinal microbiome diversity; 3. Changes in the urinary 3-indoxyl sulfate levels; 4. Changes in the serum biomarkers of intestinal permeability (lipopolysaccharides; zonulin, citrulline, and fatty acid binding proteins).

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

The Effect of Rivaroxaban in Sickle Cell Disease

NCT02072668

Sickle Cell Anemia Sickle Cell-Beta0-Thalassemia

COMPLETED PHASE2

Decitabine for High-Risk Sickle Cell Disease

NCT01375608

Neutropenia Sickle Cell Disease

COMPLETED PHASE2

Deferoxamine for Sickle Cell Chronic Leg Ulcer Treatment

NCT04058197

Chronic Cutaneous Ulcer Sickle Cell Disease

WITHDRAWN PHASE1/PHASE2

A Phase II Trial of Regadenoson in Sickle Cell Anemia

NCT01788631

Sickle Cell Anemia

COMPLETED PHASE2

Defibrotide in Sickle Cell Disease-Related Acute Chest Syndrome

NCT03805581

Sickle Cell Disease Acute Chest Syndrome

COMPLETED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

In this single-arm Phase II study, the investigators will accrue 20 SCD patients who had at least two hospital admissions in the previous 12 months to receive rifaximin 550 mg twice a day for a total of 12 months. The investigators will measure changes in the annual rate of hospital admissions due to vaso-occlusive crisis and the annual rate of hospital days. The investigators will also determine the annual rates of uncomplicated crises and acute chest syndrome. Quality of life due to the disease and to treatment will be determined using a questionnaire. This study will be complemented with exploratory laboratory studies to determine changes in the number of circulating activated neutrophils, intestinal microbiome diversity, urinary 3-indoxyl sulfate levels and serum biomarkers of intestinal permeability (lipopolysaccharides; zonulin, citrulline, and fatty acid binding proteins).

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Sickle Cell Disease Antibiotics

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Single

Each subject will receive rifaximin 550 mg twice a day for up to one year.

Group Type EXPERIMENTAL

Rifaximin

Intervention Type DRUG

Administer daily rifaximin to modify intestinal microbiome to alter the course of the disease.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Rifaximin

Administer daily rifaximin to modify intestinal microbiome to alter the course of the disease.

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Xifaxan

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Patients with HbSS, HbSC, or HbS beta thal.
2. Age 18-70 years.
3. More than two hospital admissions for painful VOC in the prior 12 months, whether on any anti-sickling agents (e.g. hydroxyurea, L-glutamine, or transfusion therapy) or not. These agents may be continued during the study period. However, subjects are not allowed to be started on any of these agents during the study period.
4. Ability to comprehend and sign an informed consent. -

Exclusion Criteria

1. Pregnant or lactating. For female subjects of child-bearing potential, the subject must agree to avoid pregnancy during the rifaximin study period and to practice a recognized form of birth control during this period (e.g. barrier, birth control pills, abstinence).
2. Life expectancy of \< 12 months.
3. History of allergy to rifaximin.
4. Patients with newly developed abnormal vital signs or abnormal physical examination (outside the signs that are expected in patients with SCD).
5. Patients in active VOC.
6. Patients with a baseline prothrombin time International Normalized ratio (INR) \>2.0.
7. Patients who receive any blood products within three weeks of the screening visit.
8. Patients with uncontrolled liver disease or renal insufficiency, colitis, or inflammatory bowel disease.
9. Patients with HIV, or other concomitant immunodeficiency.
10. Patients on penicillin prophylaxis or antibiotics for treatment of infection.
11. Patients with significant medical condition that require hospitalization (other than sickle cell VOC) within two months of the screening visit.
12. Patients currently taking or has been treated with an investigational drug within 30 days of the screening visit.

\-

Minimum Eligible Age

18 Years

Maximum Eligible Age

70 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No